Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study.
Ting DengZhigang LiuZhengquan HanHuan ZhouRui LiuYijing LiShaorong LiPeng XiuShuni WangYiping ZhangYi BaPublished in: Therapeutic advances in medical oncology (2023)
NCT04414150.
Keyphrases